KalVista Pharmaceuticals Inc (KALV) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following...

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted twelve...

Form 8-K - Current report

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its...

Form 8-K - Current report

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

–Provides up to $184 million investment to support commercial launch of sebetralstat which, if approved, will be the first and only oral...

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

–Phase 3 trial data show that early treatment is correlated with shorter attack duration– – Rigorous comparison of Phase 3 results for oral...